• Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone and is in clinical development for the treatment of SHPT in patients with CKD on hemodialysis. (finchannel.com)
  • Prevention and treatment of these complications includes effective dialysis, appropriate low-phosphate diet with limitation of the protein supply to the 0.8g/kg of the body mass, adequate calcium and active Vitamin D3 supply, introduction of the phosphate binding medications (sevelamer or lantan) as well as calcimimetic use (substances activating parathyroid gland calcium receptors inhibiting both its up-regulation and PTH secretion). (heraldopenaccess.us)
  • If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously at the end of the dialysis session, according to Amgen. (finchannel.com)
  • Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. (wikipedia.org)
  • Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)" Martin KJ, Bell G, Pickthorn K, Huang S, Vick A, Hodsman P, Peacock M (February 2014). (wikipedia.org)
  • It is available as a 150-mg oral tablet and intravenous solution. (medscape.com)
  • Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone and is in clinical development for the treatment of SHPT in patients with CKD on hemodialysis. (amgen.com)
  • Etelcalcetide is a novel calcimimetic agent in clinical development for the treatment of SHPT in CKD patients on hemodialysis that is administered intravenously at the end of the dialysis session. (amgen.com)
  • Parsabiv is a novel calcimimetic agent indicated for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. (amgen.com)
  • Treatment with an intravenous bisphosphonate or denosumab (Xgeva, Prolia) is recommended compared with management without these agents. (medscape.com)
  • Treatment with denosumab is suggested over an intravenous bisphosphonate. (medscape.com)
  • 14 mg/dL (3.5 mmol/L), a combination of calcitonin and an intravenous bisphosphonate or denosumab is suggested as initial treatment compared with only intravenous bisphosphonate or denosumab. (medscape.com)
  • For a patient with refractory/recurrent HCM on an intravenous bisphosphonate, denosumab is suggested. (medscape.com)
  • For HCM resulting from tumors associated with high calcitriol levels, such as lymphomas, and in adults already receiving glucocorticoid therapy but who continue to have severe or symptomatic hypercalcemia, the addition of an intravenous bisphosphonate or denosumab is suggested. (medscape.com)
  • Depending on the clinical situation and severity of hypercalcemia, intravenous bisphosphonate or denosumab would be useful prior to calcimimetic initiation. (medscape.com)
  • In patients with hypercalcemia as a result of parathyroid carcinoma that is not adequately controlled despite treatment with a calcimimetic, the addition of an intravenous bisphosphonate or denosumab is suggested. (medscape.com)
  • Intravenous fluids and a bisphosphonate infusion for severe or symptomatic hypercalcemia. (nih.gov)
  • Parsabiv is the first calcimimetic agent that can be administered intravenously by a healthcare provider three times a week at the end of a hemodialysis session. (amgen.com)
  • Sensipar ® (cinacalcet) is the first oral calcimimetic agent approved by the FDA for the treatment of SHPT in adult patients with CKD on dialysis. (amgen.com)
  • When the incidence of drugs will be interpreted without a unique antiviral medication guide covers calcimimetic medications down the clinical pharmacology. (myjuicecup.com)
  • Intravenous iron may be necessary for maintenance treatment of anemia associated with CKD. (medscape.com)
  • A calcimimetic is a drug that mimics the action of calcium by activating the calcium-sensing receptors on the parathyroid gland. (amgen.com)
  • Iron sucrose is a polynuclear iron (III) hydroxide in sucrose for intravenous use. (medscape.com)